Yesterday it was reported that the SVP, Secretary and GC of Insulet Corp (PODD), David Colleran, exercised options to sell 20,975 PODD shares at $35.54 a share, for a total transaction value of $1.99M.
In addition to David Colleran, 2 other PODD executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Insulet Corp’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $165 million and quarterly net profit of $9.89 million. In comparison, last year the company earned revenue of $131 million and had a GAAP net loss of $6.86 million. PODD’s market cap is $5.48B and the company has a P/E ratio of 1951.35. The Company has a Price to Book ratio of 26.1928.
One of the top 25 analysts, according to TipRanks.com, recently recommended Buy PODD with a $118 price target. Based on 8 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $102.00, reflecting a 8.7% upside.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
